MEDICALSYSTEM BIOTECHNOLOGY CO., LTD Medicalsystem Biotechnology Co., Ltd Share Price
Equities
300439
CNE100001Z25
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.28 CNY | +0.76% |
|
-0.22% | -20.07% |
| Sales 2022 | 2.49B 343M 27.12B | Sales 2023 | 1.89B 260M 20.55B | Capitalization | 4.45B 612M 48.45B |
|---|---|---|---|---|---|
| Net income 2022 | 199M 27.41M 2.17B | Net income 2023 | 257M 35.4M 2.8B | EV / Sales 2022 | 1.58 x |
| Net cash position 2022 | 555M 76.43M 6.05B | Net cash position 2023 | 872M 120M 9.5B | EV / Sales 2023 | 1.9 x |
| P/E ratio 2022 |
22.5
x | P/E ratio 2023 |
17.3
x | Employees | - |
| Yield 2022 |
0.9% | Yield 2023 |
1.15% | Free-Float | 50.8% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.76% | ||
| 1 week | -0.22% | ||
| Current month | -7.85% | ||
| 1 month | -10.08% | ||
| 3 months | -6.55% | ||
| 6 months | -20.55% | ||
| Current year | -20.07% |
1 week
9.10
9.53
1 month
8.9210.31
Current year
7.2811.86
1 year
7.2812.60
3 years
7.2829.90
5 years
7.2829.90
10 years
7.2878.84
| Managers | Title | Age | Since |
|---|---|---|---|
Ji Hua Zou
CEO | Chief Executive Officer | 45 | 31/03/07 |
Bing De Zou
FOU | Founder | 52 | 21/07/03 |
Xiao Yan Tian
CHM | Chairman | 44 | 30/09/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bing De Zou
FOU | Founder | 52 | 21/07/03 |
Ji Hua Zou
CEO | Chief Executive Officer | 45 | 31/03/07 |
Cheng Ai Li
BRD | Director/Board Member | 45 | 21/12/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 32 M€ | +4.26% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/06/24 | 9.28 | +0.76% | 2,310,800 |
| 20/06/24 | 9.21 | -2.13% | 3,129,100 |
| 19/06/24 | 9.41 | +0.32% | 2,198,200 |
| 18/06/24 | 9.38 | +0.97% | 2,280,900 |
| 17/06/24 | 9.29 | -0.11% | 2,068,700 |
End-of-day quote Shenzhen S.E., June 20, 2024
More quotes
MedicalSystem Biotechnology Co., Ltd. is a China-based company engaged in the research and development, manufacture and distribution of in-vitro diagnostic products. The Companyâs in-vitro diagnostic products include in-vitro diagnostic reagent and in-vitro diagnostic instrument. In addition, the Company is also involved in the provision of third-party medical diagnosis services, as well as the production and distribution of reagent raw materials. The Company mainly operates businesses in domestic market.
Calendar
18/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -20.07% | 491M | |
| -11.68% | 11.22B | |
| +27.58% | 5.48B | |
| +1.44% | 5.38B | |
| -17.38% | 3.77B | |
| +8.12% | 2.6B | |
| -64.90% | 2.35B | |
| -10.17% | 2.25B | |
| +26.75% | 2.2B | |
| -12.53% | 1.7B |
- Stock Market
- Equities
- 300439 Stock
